Stem Cells and Cell Therapies in Lung Biology and Diseases

描述(由申请人提供)： 利用干细胞修复和再生病变肺是治疗各种肺部疾病的一种令人兴奋的潜在治疗方法。越来越多的信息表明，正常情况下不在肺内的细胞可以用来损伤肺损伤，也可以诱导损伤后的修复和重塑。与此同时，使用人工基质作为三维肺再生框架的生物工程研究也出现了激增。将这些研究与那些利用干细胞和/或细胞疗法的研究相结合，是一个有希望的快速发展方向，但仍处于起步阶段。与这些研究进一步平行的是，人们对驻留在肺中的干细胞和/或祖细胞参与肺发育以及肺损伤后修复和重塑的分子和细胞事件的了解显著增加。 我们曾于2005年7月在佛蒙特州大学举行过两次会议。成人干细胞、肺生物学和肺部疾病，由NHBLI和囊性纤维化基金会赞助；以及2007年7月。由NHLBI通过R13会议赠款以及由Alpha 1抗胰酶基金会和肺纤维化基金会赞助的肺生物学和疾病中的干细胞和细胞疗法，聚集了相关研究人员以及感兴趣的初级教职员工和学生，讨论和讨论这个快速发展的领域的问题。这些会议非常成功，既激励了这一领域，也产生了一系列关于基础和翻译研究的指导方针，供调查人员和供资机构使用。 随着干细胞和细胞疗法治疗肺部疾病的研究继续快速发展，我们建议再次召集相关调查人员以及来自NHLBI、FDA和非营利性呼吸系统疾病基金会的代表再次辩论和讨论当前的问题。特别要讨论的一个领域是基础研究和转化性研究之间的平衡以及临床试验的作用，特别是现在已经有干细胞治疗肺动脉高压和慢性阻塞性肺病的临床试验。与以往会议一样，初级调查员和受训人员(本科生、博士后、研究员)将特别被纳入会议讨论和招贴会议。作为一个持续的特色，学员将能够基于对海报摘要的盲目审查来竞争旅游奖项。 会议计划于2009年7月在佛蒙特州大学举行。潜在参与者的热情已经很高了。我们预计，这次会议将再次促进广泛的讨论和辩论，并将显著指导干细胞和肺部疾病细胞疗法的基础和临床研究的方向。(摘要结束)

DESCRIPTION (provided by applicant): Repair and regeneration of diseased lung with stem cells is an exciting potential therapeutic approach for a variety of lung diseases. Increasing information suggests that cells normally not resident in the lung can be utilized to impair lung injury and also to induce repair and remodeling after injury. In parallel, there has been a surge in bioengineering studies investigating use of artificial matrices as framework for three dimensional lung regeneration. The combination of these studies with those utilizing stem cells and/or cell therapies is a promising rapidly developing direction but one that is still in its infancy. These studies have been further paralleled by significant increases in understanding the molecular and cellular events by which stem and/or progenitor cells resident in the lung participate in both lung development and in repair and remodeling after lung injury. We have held two previous conferences at the University of Vermont in July 2005. Adult Stem Cells, Lung Biology, and Lung Disease, sponsored by the NHBLI and Cystic Fibrosis Foundation; and in July 2007. Stem Cells and Cell Therapies in Lung Biology and Disease, sponsored by the NHLBI through an R13 conference grant as well as by the Alpha 1 Antitrypsin Foundation and Pulmonary Fibrosis Foundation, that brought together relevant investigators as well as interested junior faculty and students to debate and discuss issues in this rapidly moving field. These conferences have been very successful and have both stimulated the field and resulted in a series of guidelines for basic and translation research to be utilized by both investigators and by funding agencies. As studies of stem cell and cell therapies for lung diseases continues to move at a rapid pace, we propose to again convene the relevant investigators as well as representatives from the NHLBI, FDA, and non-profit Respiratory Disease Foundations to again debate and discuss current issues. One area in particular to be discussed is the balance between basic and translational research and the role of clinical trials, particularly as there have now been clinical trials of stem cells for pulmonary hypertension and for COPD. As in the previous conferences, junior investigators and trainees (graduate, post doctoral, fellow) will be particularly targeted for inclusion in both conference discussions as well as in poster sessions. As a continuing feature, trainees will be able to compete for travel awards based on blinded review of poster abstracts. The conference is planned for July 2009 at the University of Vermont. Enthusiasm is already high among potential participants. We anticipate that this conference will again foster extensive discussion and debate and will significantly guide the directions taken in basic and clinical research of stem cells and cell therapies for lung diseases. (End of Abstract)